220 related articles for article (PubMed ID: 35504889)
21. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
22. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase.
Vollmer O; Felten R; Mertz P; Lebrun-Vignes B; Salem JE; Arnaud L
Autoimmun Rev; 2020 Mar; 19(3):102460. PubMed ID: 31917266
[TBL] [Abstract][Full Text] [Related]
23. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
[TBL] [Abstract][Full Text] [Related]
26. Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database.
Moey MYY; Jiwani RA; Takeda K; Prenshaw K; Kreeger RW; Inzerillo J; Liles DK; Marcu CB; Lebrun-Vignes B; Morris DL; Ardhanari S; Salem JE
ESC Heart Fail; 2021 Aug; 8(4):3360-3368. PubMed ID: 33938158
[TBL] [Abstract][Full Text] [Related]
27. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
[TBL] [Abstract][Full Text] [Related]
28. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
29. Can tramadol really induce hyponatraemia? A pharmacovigilance study.
de Canecaude C; Rousseau V; Chebane L; Lafaurie M; Durrieu G; Montastruc JL
Br J Clin Pharmacol; 2021 Feb; 87(2):683-686. PubMed ID: 32470196
[TBL] [Abstract][Full Text] [Related]
30. Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Lee S; Yang JW; Jung SY; Kim MS; Yon DK; Lee SW; Kang HC; Dragioti E; Tizaoui K; Jacob L; Koyanagi A; Salem JE; Kostev K; Lascu A; Shin JI; Kim JH; Smith L
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7390-7397. PubMed ID: 34919240
[TBL] [Abstract][Full Text] [Related]
31. Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database.
Konstantinov K; Dolladille C; Gillet B; Alexandre J; Aouba A; Deshayes S; Repesse Y
Haemophilia; 2023 Jan; 29(1):186-192. PubMed ID: 36367755
[TBL] [Abstract][Full Text] [Related]
32. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
[TBL] [Abstract][Full Text] [Related]
33. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
34. Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis.
Bataille P; Lebrun-Vignes B; Bettuzzi T; Ingen-Housz-Oro S; Hadj-Rabia S; Welfringer-Morin A; Bodemer C
J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38682703
[TBL] [Abstract][Full Text] [Related]
35. Investigating the safety profiles of exogenous melatonin and associated adverse events: A pharmacovigilance study using WHO-VigiBase.
Ha M; Yoon D; Lee CY; Lee M; Kim YW; Lee JM; Shin JY
J Pineal Res; 2024 Mar; 76(2):e12949. PubMed ID: 38528668
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
39. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
Harigai M
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
[TBL] [Abstract][Full Text] [Related]
40. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
